The trial results are very promising. SBRT obviously reduces hospital visits and must save NHS costs, without losing efficacy or exacerbating the side effects of conventional radiotherapy.
For those considering SBRT as a primary treatment. This appears to be the general criteria:
Strong consensus in favour of recommending prostate SBRT as standard treatment for patients with ISUP 2 to 3, cT1c to cT2c prostate cancer with a PSA-value <20 ng/mL. Experts treating patients with high-risk disease report that prostate SBRT is generally reserved for cases without a combination of multiple high-risk factors.
Localised disease, typically clinical T1-T2 stage, with a low likelihood of extra-capsular extension, a ISUP Grade Group 2–3, PSA levels <20 ng/mL represents the clinical scenario with the strongest evidence supporting SBRT. Although a large amount of literature is based on data coming from patients with low- and intermediate-risk prostate cancer, the increasing role of active surveillance in low-risk cases means that SBRT will mainly be used for NCCN intermediate-risk prostate cancer
https://www.thegreenjournal.com/article/S0167-8140(26)00549-9/fulltext
Unfortunately, with a high Gleason score and T3a staging, it wasn't a suitable treatment option for me. However, I've always been a big fan of it. So much so, that I adapted the lyrics of Mary Poppins Supercalifragilisticexpialidocious to sing it praises. 🙂
🎵 It's Ultra-hypo-fractionated-stereotactic radiation.
Even though the sound of it can cause intrepidation.
If you say it loud enough, it'll help eradication.
Ultra-hypo-fractionated-stereotactic-radiation.
Um-dittle-ittl-um-dittle-I
Um-dittle-ittl-um-dittle-I
Um-dittle-ittl-um-dittle-I
Um-dittle-ittl-um-dittle-I 🎵
Edited by member 15 Sep 2026 at 12:51
| Reason: Additional text